Roche goes 0-2 in the high-stakes race to get a TIG­IT through PhI­II and on­to the mar­ket

Roche has racked up its sec­ond straight Phase III fail for its TIG­IT tiragolum­ab, flag­ging a flop on the pro­gres­sion-free sur­vival co-pri­ma­ry end­point for the drug com­bined with Tecen­triq as a first-line treat­ment for PD-L1 high pa­tients suf­fer­ing from non-small cell lung can­cer.

The oth­er co-pri­ma­ry end­point in the SKY­SCRAPER-01 study on over­all sur­vival hasn’t reached the read­out phase yet. But this time around Roche ex­ecs are wait­ing to see if it just might hit pos­i­tive af­ter see­ing nu­mer­i­cal gains for both end­points.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER